CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年6月22日～2025年6月28日の間に収集した論文情報を追加しました。

  1. Fluoroquinolones and risk of nightmares: A literature review and disproportionality analysis using individual case safety reports from Food and Drug Administration Adverse Event Reporting System database.

  ニューキノロン系薬剤が悪夢のリスク増加に関連

  対象DB：FAERS

  2. Adverse event profiles of four monomethyl auristatin E-conjugated antibody drug conjugates: a disproportionality analysis based on the US FDA adverse event reporting system (FAERS) database.

  MMAE-ADC関連有害事象の解析と安全性評価

  対象DB：FAERS

  3. Identifying Predictors of Serious Adverse Events in Antidepressant Treatment from a Decade-Long Nationwide Pharmacovigilance Study: Impact of Dementia and Parkinson's Disease Treatment.

  抗うつ薬関連重大有害事象の予測因子解析

  対象DB：FAERS,KAERS

  4. Explaining Uncertain Hepatoprotective Effects: When Silibinin Co-Administered with Other Drugs.

  シリビニン併用で肝毒性リスク増加の可能性

  対象DB：FAERS

  5. Towards interpretable drug interaction prediction via dual-stage attention and Bayesian calibration with active learning.

  DABI-DDIでDDI予測と生物学的解釈向上

  対象DB：FAERS

  6. Drug adverse events associated with temozolomide administration: A real-world pharmacovigilance study using the FAERS database from 2014 to 2024.

  テモゾロミドの副作用解析と新規AE特定

  対象DB：FAERS

  7. Malignant melanoma and multiple sclerosis therapies: A disproportionality analysis of the FDA adverse event reporting system.

  MS治療薬が悪性黒色腫リスクに影響の可能性

  対象DB：FAERS

  8. The Association Between Dexmedetomidine and Bradycardia: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles.

  デクスメデトミジンの徐脈リスクと遺伝子解析

  対象DB：FAERS

  9. SGLT2 inhibitors may increase creatinine clearance: data mining utilizing the FDA Adverse Event Report System database and pharmacokinetic study with rats.

  SGLT2阻害薬がクレアチニン排泄量を増加可能性

  対象DB：FAERS

  10. Real-world pharmacovigilance reports of hepatitis A inactivated and hepatitis B (recombinant) vaccine: insights from disproportionality analysis of the vaccine adverse event reporting system.

  HepABワクチンの副作用を総合的に解析評価

  対象DB：FAERS,VAERS

  11. A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database.

  ロラゼパムの安全性評価と新規副作用解析

  対象DB：FAERS

  12. Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024.

  イリノテカンの副作用を地域別に比較解析

  対象DB：FAERS,JADER

  13. An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib.

  オシメルチニブの心毒性と分子機序を解明

  対象DB：FAERS

  14. Postmarketing safety analysis of remimazolam: Identifying unlabelled serious events.

  レミマゾラムの安全性評価と副作用解析

  対象DB：FAERS,JADER

  15. Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system.

  Gepantsの副作用リスク信号を体系的に解析

  対象DB：FAERS

  16. Association Between Melatonin Receptor Agonists and Cardiac Arrhythmia; Disproportionality Analysis Studies Using Pharmacovigilance Databases.

  メラトニン受容体作動薬と心不整脈の関連評価

  対象DB：FAERS

  17. Beyond pain relief: the thrombosis threat of celecoxib.

  セレコキシブと血栓症のリスクと因果関係解析

  対象DB：CVAR,FAERS,JADER

  18. Comprehensive Analysis of Proteinuria and Nephrotic Syndrome Using the Japanese Adverse Drug Event Reporting Database.

  抗VEGF薬と蛋白尿・ネフローゼ症候群の関連解析

  対象DB：JADER

  19. Risk Factors Associated With Thrombocytopenia Induced by Intravenous Immunoglobulin Formulations: An Analysis Using the JADER database.

  IVIgによる血小板減少症のリスクと関連要因評価

  対象DB：JADER

  20. JADER Database-based Analysis of the Association Between Tranexamic Acid and Thromboembolism and Related Risk Factors.

  TXAと静脈血栓塞栓症の関連性をRWDで評価

  対象DB：JADER

  21. Time-to-Onset Analysis of Rhabdomyolysis Associated With Selective Serotonin and Serotonin-Noradrenaline Reuptake Inhibitors Using the Japanese Pharmacovigilance Database.

  SSRI/SNRIと横紋筋融解症の関連と発症時期解析

  対象DB：JADER

  22. Vonoprazan-associated Microscopic Colitis and Continued Use After Onset: A Study Using a Japanese Pharmacovigilance Database.

  ボノプラザンと顕微鏡的大腸炎の関連解析

  対象DB：JADER

  23. Analysis of Esophageal Ulcers Using the Japanese Adverse Drug Event Report Database.

  薬剤性食道潰瘍の原因薬と発症特性解析

  対象DB：JADER

  24. Severe drug-associated anaphylaxis: a complementary descriptive analyses of registry cases and spontaneous reports.

  薬剤誘発重度アナフィラキシーの分析と要因確認

  対象DB：EudraVigilance

  25. Quality of Clinical Information in Pregnancy Pharmacovigilance Data Sources-A Contribution of the ConcePTION Project.

  妊娠中の薬物曝露データの臨床品質評価

  対象DB：EudraVigilance

  26. Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data.

  COVID-19抗ウイルス薬の安全性比較分析

  対象DB：EudraVigilance

  27. Uncovering Pregnancy Exposures in Pharmacovigilance Case Report Databases: A Comprehensive Evaluation of the VigiBase Pregnancy Algorithm.

  VigiBase妊娠アルゴリズムの評価と成果解析

  対象DB：VigiBase

  28. Analysis of adverse events with ruxolitinib using real-world datasets and drug-interaction networks.

  ルキソリチニブ副作用と遺伝子相互作用解析

  対象DB：JADER

  29. Regional Disparities in Incidence, Therapeutic Approaches, and In-hospital Mortality of Critical Limb Ischemia in Japan.

  日本における重症虚血肢の地域格差分析

  対象DB：DPC

  30. Measuring frailty: a comparison of the cumulative deficit model of frailty in survey and routine data.

  高齢者における調査・ルーチンデータ間のフレイル比較

  対象DB：CPRD

  31. Metformin to treat breast cancer: An application of the prevalent new-user design for observational studies with no active comparator.

  メトホルミンと乳癌死亡率の不死時間バイアス分析

  対象DB：CPRD

  32. Incidence rates of bullous pemphigoid, herpes zoster, and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study.

  COVID-19ワクチン後の皮膚疾患発生率分析

  対象DB：CPRD

  33. Long-term nitrofurantoin use: risks and alternatives in general practice.

  長期ニトロフラントイン使用のリスクと代替策

  対象DB：CPRD

  34. Trends of long-term opioid therapy and subsequent discontinuation among people with chronic non-cancer pain in UK primary care: A retrospective cohort study.

  慢性非がん痛への長期オピオイド療法傾向分析

  対象DB：CPRD

  35. Patterns of antidepressant prescribing around pregnancy: a descriptive analysis in CPRD.

  妊娠中の抗うつ薬処方と使用状況の増加分析

  対象DB：CPRD

  36. Mortality and hospital admissions in people with eating disorders: longitudinal cohort study in secondary care-linked English primary care records.

  摂食障害の死亡率と入院率の不均衡分析

  対象DB：CPRD

  37. The legacy effect of early HbA1c control on microvascular complications and hospital admissions in type 2 diabetes: findings from a large UK study.

  2型糖尿病のHbA1c目標値と合併症リスク分析

  対象DB：CPRD

  38. Quantifying all-cause healthcare resource utilization and costs of children with mild-to-moderate long COVID in France.

  小児ロングCOVIDの医療経済的負担の分析

  対象DB：THIN

  39. Use of GLP-1 receptor agonists and risks of suicide attempts or self-harm in patients with type 2 diabetes: a multicountry self-control case series study.

  GLP-1受容体作動薬使用と自傷リスク調査

  対象DB：THIN

  40. Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study.

  インダパミド処方動向と効果比較調査

  対象DB：THIN

  41. Sex Differences in Electrolyte Disturbances Among Diuretic Users According to Renal Function and Age.

  利尿薬による電解質異常の性別・腎機能影響調査

  対象DB：DeSC

  42. Impact of 2014 Japanese practice guidelines on treatment patterns in patients with myasthenia gravis: an insurance claims database study.

  重症筋無力症治療におけるステロイド使用変化調査

  対象DB：DeSC

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み